David M. Mott, Director at Epizyme, Inc. (EPZM), bought 125,217 shares at $7.97 ($999K) on 2021-03-26, disclosed to the SEC on 2021-03-29.
Open-market purchase of $999k EPZM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.98 | 28,231 | $225K | 22.6% |
| 2 | $7.98 | 28,231 | $225K | 22.6% |
| 3 | $7.80 | 217 | $2K | 0.2% |
| 4 | $7.97 | 34,269 | $273K | 27.4% |
| 5 | $7.97 | 34,269 | $273K | 27.4% |
| Total | $7.97 avg | 125,217 |
| $999K |
| 100% |
| Filing → |
| ARDX | BUY | 2025-06-11 | $738K | — | Filing → |
| ARDX | BUY | 2025-05-19 | $329K | — | Filing → |
| ARDX | BUY | 2025-05-05 | $3.2M | — | Filing → |